FAZ-Floridsdorf Allergy Center, Vienna, Austria.
Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria.
J Allergy Clin Immunol. 2018 Jan;141(1):372-381.e3. doi: 10.1016/j.jaci.2017.04.028. Epub 2017 May 12.
Cross-reactive carbohydrate determinants (CCDs) in plants and insect venoms are a common cause of irrelevant positive test results during in vitro allergy diagnosis. We observed that some CCD-positive sera show nonspecific IgE binding even with CCD-free recombinant allergens when using the Phadia ImmunoCAP platform.
We investigated whether cellulose used as an allergen carrier in ImmunoCAP harbors residual N-glycans, causing nonspecific background binding in CCD-positive sera.
IgE binding to 6 samples of blank ImmunoCAPs coupled to either streptavidin (SA-CAP-1 or 2) or nonallergenic maltose-binding protein (MBP; MBP-CAP-1 to 4) and binding to a panel of 4 recombinant allergens were compared in CCD-positive sera before and after inhibition with a CCD inhibitor (MUXF-human serum albumin).
Of 52 CCD-positive sera (bromelain, 1.01-59.6 kilounits of antigen per liter [kU/L]) tested on SA-CAP-1, 35 (67%) showed IgE binding of greater than 0.35 kU/L (0.41-4.22 kU/L). Among those with anti-CCD IgE levels of greater than 7.0 kU/L, 90% (26/29) were positive. IgE binding to SA-CAP-1 correlated with IgE binding to bromelain (r = 0.68) and was completely abolished by serum preincubation with the CCD inhibitor (n = 15). Binding scores with SA-CAP-2 and MBP-CAP-1 to MBP-CAP-4 were generally lower but strongly correlated with those of SA-CAP-1 and bromelain. IgE reactivity of 10 CCD-positive sera (14.0-52.5 kU/L) with the recombinant allergens rPhl p 12, rFel d 1, rAra h 2, and rPru p 3 was positive to at least 1 allergen in 8 of 10 (0.36-1.63 kU/L) and borderline in 2 of 10 (0.21-0.25 kU/L). Binding correlated with antibody binding to bromelain (r = 0.61) and to all blank ImmunoCAPs (r > 0.90) and could be completely blocked by the CCD inhibitor. Overall, mean background binding to cellulose CCDs corresponded to 2% to 3% of the reactivity seen with bromelain.
Cellulose used as a solid-phase allergen carrier can contain varying amounts of CCDs sufficient to cause false-positive test results up to 2 kU/L with nonglycosylated recombinant allergens in patients with high levels of anti-CCD IgE antibodies.
植物和昆虫毒液中的交叉反应性碳水化合物决定簇(CCD)是体外过敏诊断中导致无关阳性检测结果的常见原因。我们观察到,在使用 Phadia ImmunoCAP 平台时,一些 CCD 阳性血清即使与无 CCD 的重组过敏原一起使用,也会显示出非特异性 IgE 结合。
我们研究了 ImmunoCAP 中用作过敏原载体的纤维素是否含有残留的 N-糖,导致 CCD 阳性血清中出现非特异性背景结合。
比较了 52 份 CCD 阳性血清(菠萝蛋白酶,1.01-59.6 千单位/升 [kU/L])在与链霉亲和素(SA-CAP-1 或 2)或非过敏原麦芽糖结合蛋白(MBP;MBP-CAP-1 至 4)偶联的空白 ImmunoCAP 上的 IgE 结合,以及与一组 4 种重组过敏原的结合,在使用 CCD 抑制剂(MUXF-人血清白蛋白)抑制之前和之后。
在 52 份被测试的 SA-CAP-1 上的 CCD 阳性血清(菠萝蛋白酶,1.01-59.6 千单位/升 [kU/L])中,35 份(67%)显示出大于 0.35 kU/L(0.41-4.22 kU/L)的 IgE 结合。在抗 CCD IgE 水平大于 7.0 kU/L 的 26 份中,有 90%(26/29)为阳性。SA-CAP-1 上的 IgE 结合与菠萝蛋白酶上的 IgE 结合相关(r=0.68),并且在用 CCD 抑制剂孵育血清后完全被阻断(n=15)。SA-CAP-2 和 MBP-CAP-1 至 MBP-CAP-4 的结合评分通常较低,但与 SA-CAP-1 和菠萝蛋白酶强烈相关。10 份 CCD 阳性血清(14.0-52.5 kU/L)与重组过敏原 rPhl p 12、rFel d 1、rAra h 2 和 rPru p 3 的 IgE 反应性在 8 份中的至少 1 份(0.36-1.63 kU/L)和 2 份中的边界(0.21-0.25 kU/L)为阳性。与菠萝蛋白酶(r=0.61)和所有空白 ImmunoCAP(r>0.90)的抗体结合相关,并且可以被 CCD 抑制剂完全阻断。总体而言,纤维素对 CCD 的背景结合相当于与菠萝蛋白酶相比,2%至 3%的反应性。
在抗 CCD IgE 抗体水平较高的患者中,用作固相过敏原载体的纤维素可能含有足够量的 CCD,足以导致高达 2 kU/L 的非糖基化重组过敏原的假阳性检测结果。